MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'intermune'. Sat, 03 Sep 2011 03:00:18 +0100 http://www.medworm.com/index.php?rid=3534098&cid=t_166327_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FeJcyAFFKPEM%2F Last night, a high-flying biotech, InterMune, was brought back down to earth when the FDA issued a surprise rejection of its drug to treat idiopathic pulmonary fibrosis, which Wall Street was betting would generate $1 billion a year or more in annual sales. In anticipation of approval, the stock had increased roughly five times, reaching almost $50 a share - until now. The stock is around $10. About 100,000 folks in the US suffer from this fatal lung ailment, but InterMune is unlikely to win approval any time soon, because the FDA saked for a new clinical trial of the medicine, called Esbriet or pirfenidone, to prove it delays progression. As TheStreet points out, InterMune should have raised more money after an FDA panel voted 9 to 3 to recommend approval last March. Now it has just about... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3534098 Wed, 05 May 2010 14:45:52 +0100 3534098 http://www.medworm.com/index.php?rid=3534104&cid=t_166327_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FcX71wf9ixiQ%2F Another shiny day here on the Pharmalot corporate campus, where this is much to do. You know the drill - meetings, deadlines and a blizzard of emails. Nonetheless, our spirits are equally sunny. So as prepare the required cup of stimulation, join us as we sift through the news of the world. Have a great day and do stay in touch… King Pharmaceuticals Profit Falls Short (Reuters) Aftermath Of The Intermune Debacle (TheStreet) KV Pharma Gets A Positive Manufacturing Review (Reuters) Covance Cuts Guidance On Late-Stage Delays (OutsourcingPharma) J&J Failed To Safeguard Children’s Tylenol (Bloomberg News) Merck And Ariad Restructure Agreement (MarketWatch) Drugmakers Agree To Cut Australia’s Drug Bill (Bloomberg News) Bristol-Myers To Repurchase $3B In Stock (Associated P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3534104 Wed, 05 May 2010 11:50:38 +0100 3534104 http://www.medworm.com/index.php?rid=2967533&cid=t_166327_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fb26ZIwnjIbM%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Seton Hall Law’s Center for Health & Pharmaceutical Law & Policy appointed Simone Handler-Hutchinson executive director, Global Healthcare Compliance & Ethics Education (pictured right) and hired Jes... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2967533 Fri, 06 Nov 2009 12:55:52 +0100 2967533 http://www.medworm.com/index.php?rid=2851718&cid=t_166327_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F09%2Fintermune-executive-convicted-of-fraud.html From today's New York Times comes word of an unusual legal case,In a verdict that could strike fear into pharmaceutical industry executive suites, the former head of a drug company was convicted of wire fraud Tuesday for issuing what federal prosecutors called a misleading press release that contributed to off-label sales of his company’s drug.But the executive, W. Scott Harkonen, the former chief executive of InterMune, was acquitted by the federal jury in San Francisco of a related charge of off-label marketing itself, known as 'misbranding,' the Justice Department said.The case was unusual because off-label marketing cases are often settled with the company paying a fine. It is rare for prosecutors to press charges against individual executives.'Today’s verdict demonstrates that pha... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=2851718 Wed, 30 Sep 2009 19:53:00 +0100 2851718 http://www.medworm.com/index.php?rid=2846623&cid=t_166327_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2009%2F09%2Fformer-drug-executive-convicted-of-wire.html Story (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=2846623 Wed, 30 Sep 2009 03:42:00 +0100 2846623 http://www.medworm.com/index.php?rid=1314437&cid=t_166327_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F254241420%2F W. Scott Harkonen, who once headed InterMune, was charged in federal court on Tuesday with orchestrating an off-label marketing scheme for the Actimmune drug. Harkonen was ceo from 1998 until 2003, and during that time, he is accused of making false and misleading statements about how effective the drug was in combatting a fatal lung disease, idiopathic pulmonary fibrosis, or IPF, the Associated Press writes. A press release Harkonen wrote touting the benefits of Actimmune to treat IPF in August 2002 is at the heart of the government’s case. The press release stated that a large-scale scientific test showed the drug helped IPF patients live longer, prompting many docs to write scrips even though Actimmune wasn’t approved for that disease. The Department of Justice says a specia... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1314437 Wed, 19 Mar 2008 12:00:20 +0100 1314437 http://www.medworm.com/index.php?rid=1177896&cid=t_166327_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F222926795%2F Fifteen months ago, the Department of Justice signed a deferred prosecution agreement with InterMune, where some former employees of the biotech had engaged in illegal off-label marketing of its osteoporosis drug Actimune. But as it turns out, the deal didn’t protect former execs from prosecution, and the investigation remains alive. In fact, lawyers familiar with the case say charges are likely to be brought, even though the DOJ has rarely pursued criminal charges against pharma execs at companies that settle, The Recorder reports. There is one other recent example: Purdue Pharma’s parent pled guilty to illegal marketing of its OxyContin painkiller, and three current or former execs admitted to wrongdoing last May, although they avoided jail time. So is the government starting... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1177896 Fri, 25 Jan 2008 13:45:28 +0100 1177896